The Latest Breaking News from Pfizer

A new method called ‘skeletal editing’ offers a hugely simplified way to alter matter, paving the way for world-changing innovations in personalised medicine and sustainable plastics

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

Medical journals describe all-cause mortality in randomized controlled trials (RCTs) 

 Evidence the FDA used for those decisions violates at least three safety and efficacy standards from earlier FDA publications

A tornado that ripped through a Pfizer plant in Rocky Mount, N.C., raised worries about shortages of medicines used in hospitals. The drugs include commonly used painkillers and anesthetics.

The markets have been on fire the past couple of weeks. While yesterday’s interest hike took some steam out of the markets, these three stocks and their options are unusually active and worthy of consideration.

Traders should have a bearish outlook on the stock and ideally look to enter when the stock has a high implied volatility rank.

"What we are doing now, I don’t think anyone has done so far," Pfizer CEO Albert Bourla says.

Observer investigation shows that majority of Nice drug appraisals involve groups financially linked to maker of pharmaceuticals